Anmeldung erfolgt in Kürze...
Details werden geladen...
expert reaction to trial of new amylin-based weight-loss drug petrelintide, noting fewer side effects than GLP-1-based drugs | Science Media Centre
Ähnliche Seiten
expert reaction to a systematic review and meta-analysis of GLP-1 RA exposure in the periconceptional period and adverse obstetric outcomes | Science Media Centre
https://www.sciencemediacentre.org/expert-reaction-to-a-systematic-review-and-meta-analysis-of-glp-1-ra-exposure-in-the-periconceptional-period-and-adverse-obstetric-outcomes/expert reaction to systematic review and meta-analysis of cannabis use and violence | Science Media Centre
https://www.sciencemediacentre.org/expert-reaction-to-systematic-review-and-meta-analysis-of-cannabis-use-and-violence/expert reaction to news that Open AI has halted roll out of new model over safety concerns | Science Media Centre
https://www.sciencemediacentre.org/expert-reaction-to-news-that-open-ai-has-halted-roll-out-of-new-model-over-safety-concerns/
Most powerful obesity drug yet: People lost up to 25% of weight in trial - Ars Technica
https://arstechnica.com/health/2026/09/most-powerful-obesity-drug-yet-people-lost-up-to-25-of-weight-in-trial/expert reaction to a population cohort study on prenatal exposure to maternal depression and antidepressants and neurodevelopmental outcomes | Science Media Centre
https://www.sciencemediacentre.org/expert-reaction-to-a-population-cohort-study-on-prenatal-exposure-to-maternal-depression-and-antidepressants-and-neurodevelopmental-outcomes/